ENVB Enveric Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 890821 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.4%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-204.8%
ROA-175.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.78M | $2.84M |
| SG&A expense | $5.79M | $6.45M |
| Operating income | -$8.77M | -$9.63M |
| Pretax income | -$8.77M | -$9.57M |
| Income tax | — | $8,930 |
| Net income | -$8.77M | -$9.57M |
| EBITDA | -$8.57M | -$9.29M |
| EPS (basic) | -36.24 | -228.48 |
| EPS (diluted) | -36.24 | -228.48 |
| Weighted avg. shares (diluted) | 334,719 | 41,908 |
| Banking | ||
| Net interest income | -$106 | $219 |
| Balance sheet | ||
| Cash & equivalents | $4.68M | $2.24M |
| Current assets | $4.94M | $2.73M |
| PP&E, net | $159,234 | $305,777 |
| Intangibles | — | $42,182 |
| Total assets | $5.10M | $3.08M |
| Current liabilities | $918,400 | $1.49M |
| Total liabilities | $918,400 | $1.49M |
| Shareholders' equity | $4.18M | $1.59M |
| Shares outstanding | 1.06M | 56,501 |
| Cash flow statement | ||
| Operating cash flow | -$8.14M | -$7.73M |
| Financing cash flow | $10.58M | $7.67M |
| Depreciation & amortization | $200,858 | $337,489 |
| Stock-based compensation | $827,323 | $1.56M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.